Core Insights - The treatment landscape for primary biliary cholangitis (PBC) has significantly evolved with the recent approvals of Gilead's Livdelzi (seladelpar) and Ipsen's Iqirvo (elafibranor), marking progress in disease management [1] - Pruritus remains a significant unmet need for PBC patients, with many suffering from moderate to severe symptoms that impact their quality of life [2] Treatment Developments - GSK's linerixibat, an ileal bile acid transporter (IBAT) inhibitor, has had its New Drug Application accepted by the FDA for treating cholestatic pruritus in PBC patients, with a target action date of March 24, 2026 [3] - Gastroenterologists express a high likelihood of incorporating linerixibat into treatment if approved, noting its potential for significant symptom reduction despite concerns over side effects like abdominal pain and diarrhea [3] Market Analysis - Spherix Global Insights' Market Dynamix™ service provides analysis on markets expected to undergo significant changes in the next three to five years, focusing on market size, treatment approaches, unmet needs, and expert opinions on pipeline agents [4] - The service aims to track emerging developments in the PBC treatment landscape and pipeline, highlighting the ongoing demand for effective therapies targeting pruritus [3][4]